Nasdaq
$15.44▲ 1.58%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.44BShares out 93.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 2d agoAfter-hours26.10.23 05:446-KKey event#●●●#●●●
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma purchased 200,000 existing shares on-market on October 22, 2026, to satisfy the 2022 RSU Scheme. The total consideration paid for the shares was approximately HK$5.74 million, with an average price of approximately HK$28.70 per share.…more
$15.44+1.58%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 05:556-KKey event
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma announced that its novel Bcl-2 inhibitor, lisaftoclax (APG-2575), has been granted Breakthrough Therapy Designation (BTD) by China's NMPA CDE for the treatment of treatment-naive adult patients with CLL/SLL in combination with acalabrutinib. This designation allows the company to receive priority communication and development guidance from the CDE, accelerating the clinical development and potential future regulatory approval process in China.…more
$15.44+1.58%vs prev closeView filingShare - 10.15Pre-market26.10.15 22:266-KKey event
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma purchased 200,000 existing shares on-market on October 15, 2026, to satisfy the 2022 RSU Scheme. The total consideration for the purchase was HK$5,778,916, with an average price of approximately HK$28.89 per share, and these shares will be held by the trustee for future vesting.…more
$15.44+1.58%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoOvernight26.10.21 16:35#●●●#●●●
Ascentage Pharma Receives China Breakthrough Therapy Designation for Lisaftoclax Combo…more
Ascentage Pharma has been granted Breakthrough Therapy Designation in China for its combination therapy targeting CLL/SLL. As this is a regulatory milestone without immediate revenue impact, the market sentiment remains neutral.…more
$15.44+1.58%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoAfter-hours26.10.21 08:30
●●●●●●●● ●●●●● ●●●●●●
Ascentage Pharma's lisaftoclax has received Breakthrough Therapy Designation in China for the first-line treatment of CLL/SLL. This status is expected to accelerate the clinical development and regulatory review process for the drug.…more
$15.44+1.58%vs prev close - 9.2Pre-market26.09.02 21:00
●●●●●●●● ●●●●● ●●●●●●
Ascentage Pharma announced that its management will participate in four investor conferences in New York throughout September. These sessions will include company presentations and one-on-one meetings to engage with the investment community.…more
$15.44+1.58%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report